Encontrados 4 documentos, a visualizar página 1 de 1
EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilia...
Laus, Ana Carolina; de Paula, Flavia Escremim; de Lima, Marcos Alves; Carlos, Carolina Dias; Gomes, Izabela Natalia Faria; de Marchi, PedroEpidermal growth factor (EGF) and its receptor (EGFR) play an important role in lung carcinogenesis. A functional single nucleotide polymorphism (SNP) in EGF promoter region (EGF+61 A>G-rs4444903) has been associated with cancer susceptibility. Yet, in lung cancer, the EGF+61 A>G role is unclear. The aim of this study was to evaluate the risk of lung cancer associated with EGF+61 A>G SNP in the Brazilian popula...
Mutational profle of Brazilian lung adenocarcinoma unveils association of EGFR ...
Leal, Letícia Ferro; Paula, Flávia Escremim de; De Marchi, Pedro; Viana, Luciano de Souza; Pinto, Gustavo Dix Junqueira; Carlos, Carolina DiasLung cancer is the deadliest cancer worldwide. The mutational frequency of EGFR and KRAS genes in lung adenocarcinoma varies worldwide per ethnicity and smoking. The impact of EGFR and KRAS mutations in Brazilian lung cancer remains poorly explored. Thus, we investigated the frequency of EGFR and KRAS mutations in a large Brazilian series of lung adenocarcinoma together with patients' genetic ancestry, clinicop...
AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhi...
Silva-Oliveira, Renato José; Melendez, Matias; Martinho, Olga; Zanon, Maicon F.; Viana, Luciano de Souza; Carvalho, André Lopes; Reis, R. M.Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of head and neck squamous cell carcinoma (HNSCC) tumors. Cetuximab is the first targeted (anti-EGFR) therapy approved for the treatment of HNSCC patients. However, its efficacy is limited due to primary and secondary resistance, and there is no predict biomarkers of response. New generation of EGFR inhibitors with pan HER targeting and irreve...
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
Oliveira-Silva, Renato J.; Carvalho, Ana-Carolina de; Viana, Luciano de Souza; Reis, R. M.Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In ...